French drugmaker Sanofi has agreed a potential US$2 billion deal with U.S. biotech company Translate Bio to make vaccines, expanding their ...
French drugmaker Sanofi has agreed a potential US$2 billion deal with U.S. biotech company Translate Bio to make vaccines, expanding their collaboration in development of an inoculation against COVID-19.
The deal strengthens Sanofi's credentials in a market engaged in a frantic race to find a safe and effective vaccine against the coronavirus disease that has killed more than 472,000 worldwide.The companies said they would expand their partnership to develop a wide range of mRNA vaccines. The mRNA technology, an area of Translate Bio expertise, instructs human cells to make specific proteins that produce an immune response to a disease.
Sanofi expects its mRNA COVID-19 vaccine candidate to enter clinical trials by the end of the year and, if successful, gain regulatory approval in the second half of 2021.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Sanofi eyes approval of Covid-19 vaccine by first half of 2021PARIS (REUTERS) - French drugmaker Sanofi SA said on Tuesday (June 23)it expects to get approval for the potential Covid-19 vaccine it is developing with Britain's GlaxoSmithKline Plc by the first half of next year, faster than previously anticipated.. Read more at straitstimes.com.
Read more »
Sanofi eyes approval of COVID-19 vaccine by first half of 2021French drugmaker Sanofi SA said on Tuesday it expects to get approval for the potential COVID-19 vaccine it is developing with Britain's ...
Read more »
Sanofi eyes approval of COVID-19 vaccine by first half of 2021French drugmaker Sanofi SA said on Tuesday it expects to get approval for the potential COVID-19 vaccine it is developing with Britain's ...
Read more »
Sanofi eyes approval of Covid-19 vaccine by first half of 2021PARIS (REUTERS) - French drugmaker Sanofi SA said on Tuesday (June 23)it expects to get approval for the potential Covid-19 vaccine it is developing with Britain's GlaxoSmithKline Plc by the first half of next year, faster than previously anticipated.. Read more at straitstimes.com.
Read more »
SoftBank to sell slice of T-Mobile in US$21 billion dealTOKYO (BLOOMBERG) - SoftBank Group, under pressure to raise capital after record losses in its investment business, is unloading part of its stake in wireless carrier T-Mobile US Inc in a US$21 billion (S$29.3 billion) deal.. Read more at straitstimes.com.
Read more »
Wirecard thinks its US$2.1 billion cash was a fiction in growing 'disaster'Wirecard said on Monday that 1.9 billion euros (US$2.1 billion) it had booked in its accounts likely never existed, a black hole that threatens to ...
Read more »